drugset

Drugs / NOE-115

Follow last change Nov 2025 re-read 3 minutes ago

NOE-115

Investigated by: Noema Pharma AG

Trials 1

today NCT06385795 · Ph 2

20252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT06385795	Apr 2024 → Aug 2025	—	Noema Pharma AG	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 1

Date	Issuer	Release
2025-11-06	Noema Pharma AG	Results Noema Pharma Announces Phase 2a Study Results with Cendifensine in Women with Vasomotor Symptoms (Hot Flashes) Due to Menopause noemapharma.com ↗ Noema Pharma AG today announced positive topline results from a Phase 2a, open-label study evaluating cendifensine in menopausal women experiencing moderate-to-severe vasomotor symptoms (VMS), including hot flashes and night sweats.

All press releases naming this drug 2 releases

Date	Issuer	Release
2025-11-06	Noema Pharma AG	Noema Pharma Announces Phase 2a Study Results with Cendifensine in Women with Vasomotor Symptoms (Hot Flashes) Due to Menopause noemapharma.com ↗
2024-05-22	Noema Pharma AG	Noema Pharma Announces First Patient Dosed in Phase 2a Study of NOE-115, a First-In-Class Investigational Therapy for the Treatment of Vasomotor Symptoms and Additional Symptoms Associated with Menopause noemapharma.com ↗

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	NOE-115	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06385795 ↗